Syndax Pharma (SNDX) Stock Price, Quote & News

Company Profile

Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a n...

Industry: Biotechnology

Sector: Healthcare

Phone: 781 419 1400

Website: syndax.com

Address:

730 Third Avenue, 9th Floor, New York, United States

chole1 Sep. 3 at 2:49 PM

$SNDX cross fingers that the IPF and GvHD trial are positive, would get us > 30 for good IMHO

0 · Reply

PennyPoacher Sep. 3 at 1:26 AM

$SNDX

0 · Reply

PennyPoacher Aug. 31 at 11:53 PM

$SNDX

0 · Reply

Starlord10 Aug. 26 at 9:00 PM

$SNDX Banging our head on the 200 MA (red line) all month. Once through, time for biotech catch up run.

0 · Reply

flanker30 Aug. 26 at 12:53 PM

$SNDX any views on why we are stuck under $20 for the last 6 months? Is this still a good investment medium term or have things gone south for this? KURA is up 50% from its recent lows, and we are stuck here.

1 · Reply

rabbitsoup Aug. 25 at 1:27 AM

$SNDX Second time in a week- $KURA CEO just purchased another 100,000 shares- this time at $12.39 for a total of $1,239,000 in the open market. $KURA trading at year highs. Glad I bought some as a hedge... $SNDX Your competitor is putting their $ where their mouth is. I bought more $SNDX perhaps management could as well. I am quite frustrated. Unfortunately, $SNDX has completely missed this massive biotech run. Really hope this trend reverses immediately.

1 · Reply

wntlrroal Aug. 24 at 11:21 AM

$SNDX https://invezz.com/news/2026/08/24/citi-sees-up-to-410-upside-in-2-biotech-stocks-is-the-risk-worth-it/ Buy.

0 · Reply

Quantumup Aug. 24 at 10:22 AM

Citizens reiterated $KURA at Market Outperform-$24 after Kura recently announced 2Q26 financial results. $SNDX $BMY AMGN ABBV - RHHBY Citizens said -- With the KOMZIFTI launch and multiple registrational studies underway, updated ziftomenib combo data expected at ASH, the FTI platform expected to enter registrational studies in 2028, and a cash position of $519MM, we believe Kura shares represent an attractive investment, with ~57% potential downside (bear case of $5) and ~156% potential upside (bull case of $30).

0 · Reply

Hawksssss Aug. 22 at 1:35 AM

$SNDX according to UBS, Revuforj 246 mil in 2026 and 409 mil in 2027. That means 320 mil if NiKTIMVO is 80 mil for 2026 and close to 500 mil in 2027. Up from 172 mil from 2025. That’s 86% and 60% year on year total revenue growth. Sounds awesome.

0 · Reply

Valueforall Aug. 21 at 3:56 PM

$SNDX I’m buying this bs dip and downgrade Anything under $20 is worth a pinch

0 · Reply

Syndax Announces Participation in September Investor Conferences

Aug 24, 2026, 3:46 AM EDT - 10 days ago

Citi sees up to 410% upside in 2 biotech stocks: is the risk worth it?

BMEA

2026-08-21T11:15:14.000Z - 13 days ago

Syndax price target lowered to $33 from $37 at UBS

2026-08-11T11:37:09.000Z - 23 days ago

Syndax price target lowered to $40 from $44 at JPMorgan

Aug 5, 2026, 4:01 PM EDT - 4 weeks ago

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

2026-08-05T10:05:55.000Z - 4 weeks ago

Syndax price target lowered to $38 from $40 at H.C. Wainwright

Aug 4, 2026, 4:30 PM EDT - 4 weeks ago

Syndax Pharmaceuticals Earnings Call Transcript: Q2 2026

Aug 4, 2026, 4:30 PM EDT - 4 weeks ago

Syndax Pharmaceuticals Earnings release: Q2 2026

Aug 4, 2026, 4:30 PM EDT - 4 weeks ago

Syndax Pharmaceuticals Quarterly report: Q2 2026

Aug 4, 2026, 4:30 PM EDT - 4 weeks ago

Syndax Pharmaceuticals Slides: Q2 2026

Aug 4, 2026, 4:01 PM EDT - 4 weeks ago

Syndax Reports Second Quarter 2026 Financial Results and Provides Business Update

Jul 28, 2026, 7:00 AM EDT - 5 weeks ago

Syndax to Announce Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 4, 2026

Jul 14, 2026, 8:30 AM EDT - 7 weeks ago

Syndax Pharmaceuticals Transcript: R&D Day 2026

Jul 14, 2026, 8:30 AM EDT - 7 weeks ago

Syndax Pharmaceuticals Slides: FY 2026

Jul 14, 2026, 8:30 AM EDT - 7 weeks ago

Syndax Pharmaceuticals Press release: FY 2026

Jul 14, 2026, 8:00 AM EDT - 7 weeks ago

Syndax to Highlight Late-Stage Programs and Unveil New Pipeline Assets at R&D Event

2026-06-12T11:11:01.000Z - 2 months ago

Syndax price target lowered to $31 from $34 at Guggenheim

KURA

2026-06-11T12:20:39.000Z - 2 months ago

Syndax presents data from SAVE trial at EHA

Jun 11, 2026, 7:03 AM EDT - 2 months ago

Syndax Showcases Revuforj® (revumenib) Clinical Activity in Multiple Acute Leukemia Subtypes and Settings at EHA 2026

$Syndax Announces Publication of SAVE Data on Revuforj® (revumenib) in Combination with Decitabine/Cedazuridine and Venetoclax in Relapsed/Refractory NPM1m, KMT2Ar, and NUP98r AML in the Journal of Clinical Oncology$

Jun 11, 2026, 7:00 AM EDT - 2 months ago

Syndax Announces Publication of SAVE Data on Revuforj® (revumenib) in Combination with Decitabine/Cedazuridine and Venetoclax in Relapsed/Refractory NPM1m, KMT2Ar, and NUP98r AML in the Journal of Clinical Oncology

Jun 10, 2026, 12:00 PM EDT - 2 months ago

Syndax Pharmaceuticals Transcript: AGM 2026

Jun 8, 2026, 2:00 PM EDT - 2 months ago

Syndax Pharmaceuticals Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 4, 2026, 9:20 AM EDT - 3 months ago

Syndax Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2026

Jun 4, 2026, 8:00 AM EDT - 3 months ago

Syndax Pharmaceuticals Proxy statement: Proxy filing

2026-06-04T11:41:28.000Z - 3 months ago

Syndax announces $250M convertible senior note offering due 2031

Jun 4, 2026, 7:00 AM EDT - 3 months ago

Syndax Announces Private Placement of $250.0 Million of Convertible Senior Notes

Jun 2, 2026, 4:01 PM EDT - 3 months ago

Syndax Highlights Revuforj® (revumenib) Data Presented at ASCO 2026, Including an Oral Presentation of Post-Transplant Data

Jun 1, 2026, 7:00 AM EDT - 3 months ago

Syndax to Host R&D Day Highlighting its Late-Stage Programs and Early-Stage Assets on July 14, 2026

May 27, 2026, 1:00 PM EDT - 3 months ago

Syndax Pharmaceuticals Transcript: 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA

May 21, 2026, 5:01 PM EDT - 3 months ago

Syndax Announces Four Revuforj® (revumenib) Abstracts Accepted for ASCO 2026, Including an Oral Presentation of Post-Transplant Data

May 20, 2026, 7:00 AM EDT - 3 months ago

Syndax Announces Participation in Upcoming Investor Conferences

2026-05-13T12:20:45.000Z - 3 months ago

Syndax price target lowered to $37 from $38 at UBS

2026-05-12T18:34:41.000Z - 3 months ago

Syndax reports 12 Revuforj abstracts accepted for EHA

May 12, 2026, 10:31 AM EDT - 3 months ago

Syndax Highlights 12 Revuforj® (revumenib) Abstracts Accepted for EHA 2026, Advancing Leadership in Menin Inhibition

2026-05-04T10:54:25.000Z - 4 months ago

Syndax price target raised to $46 from $45 at Stifel

2026-05-01T19:25:20.000Z - 4 months ago

Syndax price target lowered to $37 from $40 at Jefferies

2026-05-01T09:40:18.000Z - 4 months ago

Syndax price target raised to $37 from $35 at Barclays

Apr 30, 2026, 4:30 PM EDT - 4 months ago

Syndax Pharmaceuticals Earnings Call Transcript: Q1 2026

Apr 30, 2026, 4:30 PM EDT - 4 months ago

Syndax Pharmaceuticals Earnings release: Q1 2026

Apr 30, 2026, 4:30 PM EDT - 4 months ago

Syndax Pharmaceuticals Quarterly report: Q1 2026

Apr 30, 2026, 4:30 PM EDT - 4 months ago

Syndax Pharmaceuticals Slides: Q1 2026

Apr 30, 2026, 4:01 PM EDT - 4 months ago

Syndax Reports First Quarter 2026 Financial Results and Provides Business Update

Apr 30, 2026, 8:00 AM EDT - 4 months ago

Syndax Pharmaceuticals Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 4 months ago

Syndax Pharmaceuticals Proxy statement: Proxy filing

Apr 24, 2026, 7:00 AM EDT - 4 months ago

Syndax to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on April 30, 2026

2026-03-31T11:13:38.000Z - 5 months ago

Syndax price target raised to $34 from $28 at Goldman Sachs

2026-03-31T11:08:14.000Z - 5 months ago

Syndax price target lowered to $43 from $45 at Mizuho

2026-03-30T13:08:09.000Z - 5 months ago

Syndax assumed with a Buy at Jefferies

KURA

Mar 12, 2026, 11:00 AM EDT - 5 months ago

Syndax Pharmaceuticals Transcript: Barclays 28th Annual Global Healthcare Conference

Mar 11, 2026, 10:00 AM EDT - 5 months ago

Syndax Pharmaceuticals Transcript: Leerink Global Healthcare Conference 2026

2026-03-09T11:11:49.000Z - 5 months ago

Syndax price target raised to $45 from $33 at JPMorgan

Mar 2, 2026, 1:50 PM EST - 6 months ago

Syndax Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference

2026-03-02T11:59:34.000Z - 6 months ago

Syndax price target raised to $57 from $51 at Citi

Feb 27, 2026, 7:00 AM EST - 6 months ago

Syndax Pharmaceuticals Slides: Corporate presentation

2026-02-26T21:39:29.000Z - 6 months ago

Syndax reports Q4 EPS (78c), consensus (58c)

Feb 26, 2026, 4:30 PM EST - 6 months ago

Syndax Pharmaceuticals Earnings Call Transcript: Q4 2025

Feb 26, 2026, 4:30 PM EST - 6 months ago

Syndax Pharmaceuticals Annual report: Q4 2025

Feb 26, 2026, 4:30 PM EST - 6 months ago

Syndax Pharmaceuticals Earnings release: Q4 2025

Feb 26, 2026, 4:30 PM EST - 6 months ago

Syndax Pharmaceuticals Slides: Q4 2025

Feb 26, 2026, 4:01 PM EST - 6 months ago

Syndax Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Feb 23, 2026, 7:00 AM EST - 6 months ago

Syndax Announces Participation in March Investor Conferences

Feb 19, 2026, 7:00 AM EST - 6 months ago

Syndax to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call and Webcast on February 26, 2026

Feb 12, 2026, 12:30 PM EST - 6 months ago

Syndax Pharmaceuticals Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Feb 5, 2026, 7:00 AM EST - 7 months ago

Syndax Announces Participation at the 2026 Guggenheim Emerging Outlook: Biotech Summit

Jan 12, 2026, 6:00 PM EST - 7 months ago

Syndax Pharmaceuticals Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 6:00 PM EST - 7 months ago

Syndax Pharmaceuticals Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 7:00 AM EST - 7 months ago

Syndax Reports Preliminary 2025 Financial Highlights and Provides Business Updates at the 44th Annual J.P. Morgan Healthcare Conference

Jan 7, 2026, 7:00 AM EST - 7 months ago

Syndax and World Orphan Drug Alliance to Launch a Multi-Regional Managed Access Program, Expanding Access to Revuforj® (revumenib) Outside the U.S.

Jan 5, 2026, 7:00 AM EST - 8 months ago

Syndax Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference

Dec 12, 2025, 7:00 AM EST - 8 months ago

Revuforj® (revumenib) Named Best New Drug at the Scrip Awards 2025

Dec 8, 2025, 7:00 AM EST - 8 months ago

Syndax Pharmaceuticals Transcript: Investor Update

Dec 8, 2025, 7:00 AM EST - 8 months ago

Syndax Pharmaceuticals Press release: Investor Update

Dec 8, 2025, 7:00 AM EST - 8 months ago

Syndax Pharmaceuticals Slides: Investor Update

Dec 8, 2025, 6:50 AM EST - 8 months ago

Syndax Highlights Leadership in Menin Inhibition at ASH 2025 with Multiple Revuforj® (revumenib) Presentations Spanning the Acute Leukemia Treatment Continuum

Dec 4, 2025, 11:15 AM EST - 9 months ago

Syndax Pharmaceuticals Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 1, 2025, 7:00 AM EST - 9 months ago

Syndax Announces Participation at the 8th Annual Evercore Healthcare Conference

Nov 20, 2025, 5:00 AM EST - 9 months ago

Syndax Pharmaceuticals Transcript: Jefferies London Healthcare Conference 2025

Nov 13, 2025, 10:00 AM EST - 9 months ago

Syndax Pharmaceuticals Transcript: Stifel 2025 Healthcare Conference

Nov 11, 2025, 3:00 PM EST - 9 months ago

Syndax Pharmaceuticals Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 10, 2025, 11:00 AM EST - 9 months ago

Syndax Pharmaceuticals Transcript: UBS Global Healthcare Conference 2025

Nov 9, 2025, 6:00 PM EST - 9 months ago

Syndax Pharmaceuticals Slides: Corporate Presentation

Nov 3, 2025, 4:30 PM EST - 10 months ago

Syndax Pharmaceuticals Earnings Call Transcript: Q3 2025

Nov 3, 2025, 4:30 PM EST - 10 months ago

Syndax Pharmaceuticals Quarterly report: Q3 2025

Nov 3, 2025, 4:30 PM EST - 10 months ago

Syndax Pharmaceuticals Earnings release: Q3 2025

Nov 3, 2025, 4:30 PM EST - 10 months ago

Syndax Pharmaceuticals Slides: Q3 2025

Nov 3, 2025, 4:01 PM EST - 10 months ago

Syndax Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 3, 2025, 9:08 AM EST - 10 months ago

Syndax Announces Compelling Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) Data Accepted for Presentation at ASH 2025

Nov 3, 2025, 9:08 AM EST - 10 months ago

Syndax to Host ASH Investor Event in Person and via Webcast on December 8, 2025

Oct 30, 2025, 7:00 AM EDT - 10 months ago

Syndax Announces Participation in November Investor Conferences

Oct 27, 2025, 7:00 AM EDT - 10 months ago

Syndax to Announce Third Quarter 2025 Financial Results and Host Conference Call and Webcast on November 3, 2025

Oct 24, 2025, 2:30 PM EDT - 10 months ago

Syndax Pharmaceuticals Transcript: Study Update

Oct 24, 2025, 2:30 PM EDT - 10 months ago

Syndax Pharmaceuticals Press release: Study Update

Oct 24, 2025, 2:30 PM EDT - 10 months ago

Syndax Pharmaceuticals Slides: Study Update

$Syndax Announces FDA Approval of Revuforj® (revumenib) in Adult and Pediatric Patients with Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia$

Oct 24, 2025, 1:58 PM EDT - 10 months ago

Syndax Announces FDA Approval of Revuforj® (revumenib) in Adult and Pediatric Patients with Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia

$Syndax's Revuforj® (revumenib) Included in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for the Treatment of Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia$

Sep 19, 2025, 7:00 AM EDT - 11 months ago

Syndax's Revuforj® (revumenib) Included in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for the Treatment of Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia

Sep 8, 2025, 9:00 AM EDT - 12 months ago

Syndax Pharmaceuticals Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 2, 2025, 4:45 PM EDT - 1 year ago

Syndax Pharmaceuticals Transcript: Citi's Biopharma Back to School Conference

Aug 26, 2025, 7:00 AM EDT - 1 year ago

Syndax Announces Participation in September Investor Conferences

Aug 19, 2025, 7:00 AM EDT - 1 year ago

Syndax Pharmaceuticals Slides: Corporate Presentation

Aug 4, 2025, 4:30 PM EDT - 1 year ago

Syndax Pharmaceuticals Earnings Call Transcript: Q2 2025

Aug 4, 2025, 4:30 PM EDT - 1 year ago

Syndax Pharmaceuticals Quarterly report: Q2 2025

Aug 4, 2025, 4:30 PM EDT - 1 year ago

Syndax Pharmaceuticals Earnings release: Q2 2025

Aug 4, 2025, 4:30 PM EDT - 1 year ago

Syndax Pharmaceuticals Slides: Q2 2025

Aug 4, 2025, 4:01 PM EDT - 1 year ago

Syndax Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 28, 2025, 7:00 AM EDT - 1 year ago

Syndax to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 4, 2025

$Syndax Announces FDA Priority Review of sNDA for Revuforj® (revumenib) in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia$

Jun 24, 2025, 4:01 PM EDT - 1 year ago

Syndax Announces FDA Priority Review of sNDA for Revuforj® (revumenib) in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia

Jun 12, 2025, 12:02 PM EDT - 1 year ago

Syndax Announces Publication of Revumenib Data from the BEAT AML Trial in the Journal of Clinical Oncology and Simultaneous Presentation at EHA 2025

$Syndax Presents New Revuforj® (revumenib) Data in Relapsed/Refractory mNPM1 and NUP98r Acute Leukemia from AUGMENT-101 Trial at EHA 2025$

Jun 12, 2025, 7:00 AM EDT - 1 year ago

Syndax Presents New Revuforj® (revumenib) Data in Relapsed/Refractory mNPM1 and NUP98r Acute Leukemia from AUGMENT-101 Trial at EHA 2025

Jun 11, 2025, 2:00 PM EDT - 1 year ago

Syndax Pharmaceuticals Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Jun 5, 2025, 1:25 PM EDT - 1 year ago

Syndax Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2025

May 30, 2025, 7:00 AM EDT - 1 year ago

Syndax Pharmaceuticals Slides: Corporate Presentation

May 29, 2025, 7:00 AM EDT - 1 year ago

Syndax Announces Participation in June Investor Conferences

May 28, 2025, 10:30 AM EDT - 1 year ago

Syndax Pharmaceuticals Transcript: 6th Annual Oncology Innovation Summit

May 15, 2025, 12:20 PM EDT - 1 year ago

Syndax Pharmaceuticals Transcript: BofA Securities 2025 Healthcare Conference

May 14, 2025, 9:30 AM EDT - 1 year ago

Syndax Announces Data Presentations at EHA 2025 Showcasing Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr)

May 12, 2025, 4:01 PM EDT - 1 year ago

Syndax Pharmaceuticals Appoints Dr. Nicholas Botwood as Head of Research and Development and Chief Medical Officer

May 8, 2025, 7:00 AM EDT - 1 year ago

Syndax Announces Participation in May Investor Conferences

$Syndax Announces Publication of Pivotal Revumenib Data in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia in the Journal Blood$

May 7, 2025, 4:01 PM EDT - 1 year ago

Syndax Announces Publication of Pivotal Revumenib Data in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia in the Journal Blood

May 5, 2025, 4:30 PM EDT - 1 year ago

Syndax Pharmaceuticals Earnings Call Transcript: Q1 2025

May 5, 2025, 4:30 PM EDT - 1 year ago

Syndax Pharmaceuticals Quarterly report: Q1 2025

May 5, 2025, 4:30 PM EDT - 1 year ago

Syndax Pharmaceuticals Earnings release: Q1 2025

May 5, 2025, 4:30 PM EDT - 1 year ago

Syndax Pharmaceuticals Slides: Q1 2025

May 5, 2025, 4:01 PM EDT - 1 year ago

Syndax Reports First Quarter 2025 Financial Results and Provides Business Update

Apr 28, 2025, 7:00 AM EDT - 1 year ago

Syndax to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 5, 2025

Apr 9, 2025, 10:30 AM EDT - 1 year ago

Syndax Pharmaceuticals Transcript: Stifel 2025 Virtual Targeted Oncology Forum

Apr 2, 2025, 7:00 AM EDT - 1 year ago

Syndax Announces Participation at the Stifel 2025 Virtual Targeted Oncology Forum

Apr 1, 2025, 8:00 AM EDT - 1 year ago

Syndax Pharmaceuticals Proxy statement: Proxy Filing

Apr 1, 2025, 8:00 AM EDT - 1 year ago

Syndax Pharmaceuticals Proxy statement: Proxy Filing

Mar 13, 2025, 8:30 AM EDT - 1 year ago

Syndax Pharmaceuticals Transcript: Barclays 27th Annual Global Healthcare Conference

Mar 4, 2025, 3:10 PM EST - 1 year ago

Syndax Pharmaceuticals Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 3, 2025, 8:00 AM EST - 1 year ago

Syndax Pharmaceuticals Earnings Call Transcript: Q4 2024

Mar 3, 2025, 8:00 AM EST - 1 year ago

Syndax Pharmaceuticals Annual report: Q4 2024

Mar 3, 2025, 8:00 AM EST - 1 year ago

Syndax Pharmaceuticals Earnings release: Q4 2024

Mar 3, 2025, 8:00 AM EST - 1 year ago

Syndax Pharmaceuticals Slides: Q4 2024

Mar 3, 2025, 7:01 AM EST - 1 year ago

Syndax Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Feb 24, 2025, 7:00 AM EST - 1 year ago

Syndax to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call and Webcast on March 3, 2025

Feb 19, 2025, 9:00 AM EST - 1 year ago

Syndax Pharmaceuticals Transcript: Citi's 2025 Virtual Oncology Leadership Summit

Feb 10, 2025, 5:42 PM EST - 1 year ago

Kuehn Law Encourages Investors of Syndax Pharmaceuticals, Inc. to Contact Law Firm

chole1 Sep. 3 at 2:49 PM

$SNDX cross fingers that the IPF and GvHD trial are positive, would get us > 30 for good IMHO

0 · Reply

PennyPoacher Sep. 3 at 1:26 AM

$SNDX

0 · Reply

PennyPoacher Aug. 31 at 11:53 PM

$SNDX

0 · Reply

Starlord10 Aug. 26 at 9:00 PM

$SNDX Banging our head on the 200 MA (red line) all month. Once through, time for biotech catch up run.

0 · Reply

flanker30 Aug. 26 at 12:53 PM

1 · Reply

rabbitsoup Aug. 25 at 1:27 AM

1 · Reply

wntlrroal Aug. 24 at 11:21 AM

$SNDX https://invezz.com/news/2026/08/24/citi-sees-up-to-410-upside-in-2-biotech-stocks-is-the-risk-worth-it/ Buy.

0 · Reply

Quantumup Aug. 24 at 10:22 AM

0 · Reply

Hawksssss Aug. 22 at 1:35 AM

0 · Reply

Valueforall Aug. 21 at 3:56 PM

$SNDX I’m buying this bs dip and downgrade Anything under $20 is worth a pinch

0 · Reply

Valueforall Aug. 21 at 1:05 PM

$SNDX Hmm. The down grade reads like an upgrade but wait that doesn’t make sense. Oh yeah they want our shares

1 · Reply

Quantumup Aug. 21 at 12:47 PM

UBS⬇️ $SNDX's PT to $33 from $37 and reiterated Buy $KURA $AZN ABBV - RHHBY SNY INCY ABBV - JNJ Here's what UBS said in its note to investors: https://x.com/Quantumup1/status/2090782730405437937?s=20

0 · Reply

Cabasada Aug. 19 at 11:01 PM

$SNDX The top 10 worst investments I've ever made

3 · Reply

Valueforall Aug. 18 at 2:28 PM

$KURA CEO buying here reminds me of $TGTX buying $1M+ in the 8’s. How did that work out for investors? As our good friend @Night_Owl_Biotech has suggested it’s time for SNDX to make a move. With revumenib (SNDX-5613) charging toward its own commercial inflection and Niktimvo expanding their oncology footprint, Syndax is being priced like a secondary clinical play despite trading at a ~$1.8B market cap with two derisked assets nearing major commercial scale. When class-wide sentiment shifts, the market catches up to the commercial leader fast. Watching for $SNDX to close that valuation arbitrage

1 · Reply

Valueforall Aug. 17 at 9:38 PM

$KURA When an insider drops $1.11M of their own cash on open-market shares at $11.12, it isn’t routine compensation management—it’s an unmistakable signal of conviction. Dr. Troy Wilson has a proven playbook for building and monetizing platforms, and seeing him deploy capital this aggressively into $KURA tells you everything about how management views current levels. This isn't just a catalyst for Kura—it’s a macro tide lifting the entire menin space. A strong vote of confidence like this validates the entire commercial asset class for $SNDX as well. When the leader of the pack buys heavy, the whole field is undervalued

0 · Reply

rabbitsoup Aug. 17 at 9:05 PM

$SNDX $KURA Ceo just purchased 100k shares in the open market $11.12/share. How about $SNDX management step up.

0 · Reply

jeffrman777 Aug. 17 at 7:13 PM

$SNDX In the shorter term, Syndax really need those readouts to hit in Q4. Existing indications aren’t providing enough growth it seems so this thing might continue to be a bit turgid. Longer term, obviously frontline is the focus and their new MF asset is one to keep an eye on.

0 · Reply

Valueforall Aug. 17 at 4:04 PM

$KURA people tend to bash the competition but I honestly love the pair trade $SNDX + $KURA - = dreamy!!!!! La isla Bonita!

0 · Reply

Valueforall Aug. 16 at 6:20 PM

$SNDX The market treats menin inhibition like a zero-sum deathmatch, but Syndax (⁠Revuforj⁠) and Kura (⁠Komzifti⁠) target distinct genetic niches with SNDX anchors KMT2A acute leukemias, while Kura zeroes in on NPM1-mutated AML. With a multi-billion-dollar addressable population across frontline combinations and chronic maintenance settings, there’s more than enough commercial room for both platforms to generate massive Blockbuster revenues without cannibalizing each other. 🧬💎 🚫 DO NOT FOLLOW ME. I post for my own science log and balance sheet math, not retail cheerleading.

2 · Reply

wntlrroal Aug. 14 at 11:54 AM

$SNDX https://www.pharmexec.com/view/what-c-suite-readiness-really-requires

0 · Reply

Magnificient Aug. 14 at 5:30 AM

$SNDX what do you think about KURA and competition?

1 · Reply

Hawksssss Aug. 14 at 2:00 AM

$SNDX Syndax has the advatange of both NPM1 and KMT2A indication approved versus Kura only for NPM1. We also have NiKTIMVO approval. The race of course is for 1L AML between the two companies. It seems Syndax will get phase 3 readout for 1L NOM1 in June 2027 versus Kura March 2028

1 · Reply

Market Cap	1.78B
Revenue (ttm)	172.35M
Net Income (ttm)	-285.42M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-165.60%
Debt to Equity Ratio	16.16

Volume	1,920,700
Avg Vol	1,652,698
Day's Range	N/A - N/A
Shares Out	88.61M
Stochastic %K	89%
Beta	0.37
Analysts	Strong Sell
Price Target	$37.25